Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II Study

NCT05024214 is registered in ClinicalTrials.gov with 3D Medicines (Sichuan) Co., Ltd. as lead sponsor.

NCT NCT05024214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05024214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Envafolimab(KN035) in Combination With Lenvatinib in the Treatment of Advanced Solid Tumors: a Multicenter, Open-label, Phase Ib/II Study
Lead sponsor
3D Medicines (Sichuan) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 15, 2021
Completion date
December 31, 2026
Enrollment
170 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, non-small cell lung cancer, renal cell carcinoma, solid tumors